Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A pilot study was performed to assess the role of cyclosporin in the management of severe inflammatory bowel disease. Twelve patients with Crohn's disease and 12 with ulcerative colitis were admitted to hospital with a severe attack. They were treated with an intravenous regimen of corticosteroids for 5 days followed by oral therapy. In addition, they received a 6-week course of oral cyclosporin, initially 15 mg kg-1 day-1 reduced to 7.5 mg kg-1 day-1. In comparison with historical controls, the addition of cyclosporin to standard corticosteroid therapy appeared to have no benefit. Adverse effects were common but minor. The expression of Class II molecules on the inflamed epithelium was rapidly reversed by cyclosporin therapy which may indicate a potential therapeutic benefit over longer periods of time.

Type

Journal article

Journal

Aliment Pharmacol Ther

Publication Date

04/1989

Volume

3

Pages

143 - 149

Keywords

Adolescent, Adult, Aged, Colitis, Ulcerative, Crohn Disease, Cyclosporins, HLA-D Antigens, Humans, Inflammatory Bowel Diseases, Middle Aged, Pilot Projects